about
Infection Control for Drug-Resistant Tuberculosis: Early Diagnosis and Treatment Is the KeyImpact of Decentralized Care and the Xpert MTB/RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South AfricaPublic-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland comparedLoss from treatment for drug resistant tuberculosis: risk factors and patient outcomes in a community-based program in Khayelitsha, South AfricaNevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South AfricaCorrecting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis.AIDS-associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South AfricaTemporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007.The effect of complete integration of HIV and TB services on time to initiation of antiretroviral therapy: a before-after study.Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trialEffectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South AfricaTreatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort studyVirologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success.Enhanced ex vivo stimulation of Mycobacterium tuberculosis-specific T cells in human immunodeficiency virus-infected persons via antigen delivery by the Bordetella pertussis adenylate cyclase vector.Superior virologic and treatment outcomes when viral load is measured at 3 months compared to 6 months on antiretroviral therapyEffect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic.'I Know that I Do Have HIV but Nobody Saw Me': Oral HIV Self-Testing in an Informal Settlement in South Africa.Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndromeAccuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy - the IeDEA Southern Africa CollaborationWho Needs to Be Targeted for HIV Testing and Treatment in KwaZulu-Natal? Results From a Population-Based Survey.Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 TargetsProvision of antiretroviral therapy in South Africa: the nuts and bolts.The uncertain future of lay counsellors: continuation of HIV services in Lesotho under pressure.Community-supported models of care for people on HIV treatment in sub-Saharan Africa.Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection.Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa.Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: A feasibility study in rural Lesotho.Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa.Cohort Profile: The Khayelitsha antiretroviral programme, Cape Town, South Africa.Adherence clubs for long-term provision of antiretroviral therapy: cost-effectiveness and access analysis from Khayelitsha, South Africa.Supervised oral HIV self-testing is accurate in rural KwaZulu-Natal, South Africa.A comparison of self-report and antiretroviral detection to inform estimates of antiretroviral therapy coverage, viral load suppression and HIV incidence in Kwazulu-Natal, South Africa.Is it safe to drop CD4+ monitoring among virologically suppressed patients: a cohort evaluation from Khayelitsha, South Africa.Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans.Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa.Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.Higher risk sexual behaviour is associated with unawareness of HIV-positivity and lack of viral suppression - implications for Treatment as Prevention.Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.South African HIV self-testing policy and guidance considerations.
P50
Q28393098-40BB5FD4-4AC2-4AF5-9376-B08482D4CC91Q28394564-8E4A1F87-87BD-4FC3-9F63-6E1FB683ED70Q28473120-4328399E-ED06-4F5B-B199-B4E0BF393780Q28544642-E5A45875-EEE8-4EC2-ACAB-6473DDB446D0Q33533366-4FB8E619-E16F-43AE-8765-6C2AAB35CD1EQ33838306-2797BFB6-116D-42E6-933E-616F211CA7F9Q34039651-473923DE-C0FB-44F8-98B3-D7944D90DD48Q34166980-FEEBDA03-D00A-4340-850F-9DBD2AD8C3C8Q34447727-4DA44283-C0DB-4BF1-BB5D-6404871284B7Q34519039-3D07CA1D-F757-49B4-90A8-BBCB02640018Q34589834-480330D4-B761-48C1-92FB-DAB674B77104Q34765704-22EAA9B7-97E5-486A-9C5D-E4E67DA29D18Q35014160-8546E9A3-0A7B-458C-9CB5-495D8E79CBCDQ35837236-FF974F05-126E-4833-A1E2-20207B16545EQ35946908-E1388AB7-B632-4231-8173-5690AE96709CQ36090721-80CB7176-22C4-4FD3-9048-B646953DD583Q36408928-C781D2F5-FD68-48EA-B08B-A60624090531Q36763471-636C743B-0B84-42BC-B04F-4B1D96C37F4EQ37098501-8CB39C02-2A9F-4F90-BD05-8B70D3A8F56EQ37199247-2F286702-83FC-4449-877B-90AFD6BFFC0AQ37519800-B1147269-BD34-40F6-AFDD-825BEFB326E1Q37710293-0D3CDAE5-FBA6-4963-B6F3-EE48C95DFD08Q38259626-AD10A057-1CB5-4584-8339-C8952F92F67FQ38627527-8BF67316-6447-4C38-9D98-0D5435DC18D3Q38901618-403EFF79-81DA-46C4-BF66-828E7A0D8779Q39777998-0DEE2830-1B21-4C93-BCF4-D29F0EEA62A3Q39911557-56F6D82B-3257-4C3C-A828-7ED90AD120F6Q40055779-E2D72B0A-4B84-40A8-A6BE-DDA6F50FCDFBQ40180199-522FD58F-0F49-49BB-A04C-2109314B3FB4Q40665399-172DE306-E87F-4BFA-ACC5-18BC459E9898Q40701983-80CAB47C-8A8C-4BAD-9AEC-906F0F7504C8Q40706029-B5722909-5861-434E-8343-5FB430DCB745Q41926207-19DB1431-6C42-47A1-93E4-87F469610E43Q42201359-FF902B76-467A-4A82-A4A3-F7DE6AE604D9Q46168249-E3DFD46F-F4FF-4C7A-8E09-A605F5D8A88FQ46374143-A09E092E-F91E-4CE8-AAB4-CF9731CE6999Q46447967-73AC113B-5A01-4741-92C0-BFE9E43E6103Q46830188-078D11ED-A8FF-4277-B9E5-CE55B3083C16Q46838565-A4210B50-26E3-4A13-B227-A0BC9E07E910Q52641450-3395A727-15BD-4615-B997-13BF45776C0F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gilles Van Cutsem
@ast
Gilles Van Cutsem
@en
Gilles Van Cutsem
@es
Gilles Van Cutsem
@nl
type
label
Gilles Van Cutsem
@ast
Gilles Van Cutsem
@en
Gilles Van Cutsem
@es
Gilles Van Cutsem
@nl
prefLabel
Gilles Van Cutsem
@ast
Gilles Van Cutsem
@en
Gilles Van Cutsem
@es
Gilles Van Cutsem
@nl
P106
P1153
24768129500
P21
P31
P496
0000-0002-8972-4480